Mark E. Rose, Chair and CEO of Avison Young, the world’s fastest-growing
commercial real estate services firm, today announced the formation of a new life sciences specialty practice group. The group, which will assist life sciences companies with their real estate needs, is led by Jerry Keeney, Avison Young Principal and Managing Director of the firm’s San Diego office; Principal
Brian Cooper, who is also based in San Diego; New Jersey-based Principal Tom Giannone; and Steve Bleiweiss, a Senior Vice-President in the firm’s Metropark, NJ office.
The group will span 10 regional markets in the U.S., Canada, Mexico and Europe and comprise 17 Avison Young leasing professionals.
“The new practice group’s members understand the pharmaceutical product life cycle as well as the technical complexities that can create budgetary and scheduling risk associated with life sciences firms’ real estate requirements,” comments Rose.
Some of these requirements include laboratories, vivariums, pilot plants and manufacturing facilities. Group members will thoroughly address risks in the planning, designing, engineering and construction phases of life science spaces. The members of Avison Young’s new life sciences specialty practice group are industry veterans with decades of proven experience representing life science companies globally.
“This experience empowers us to seamlessly service all aspects of our clients’ real estate needs, including site selection and evaluation, lease negotiation, construction management and postlease project management,” adds Rose.
Keeney notes: “The life-sciences industry is expanding at a rapid pace, accounting for much of the leasing activity in markets such as San Francisco, Boston and San Diego. The launch of our partnership at the global level allows us to formulate solutions for our clients who often have operations in more than one location.”
The centrepiece of the group’s unique approach will be a focus on integrating each client’s technical and financial requirements into the lease-negotiation process, ensuring that requirements are appropriately incorporated within transaction documents. This process will foster the development of innovative strategies with credible budgets and schedules in early stages of transactions, providing clients with the facts needed to make more fully informed decisions.
Furthermore, Avison Young’s value-engineering tools will ensure that real estate solutions are planned, designed and implemented with requisite scalability and completed under budget and on schedule, optimizing each client’s real estate assets.
“Our new life sciences specialty practice group has created a transparent, risk-averse model that enables us to work with our clients’ internal resources on either a single transaction or for their entire portfolio,” concludes Giannone.
For more information on Avison Young’s new life sciences specialty practice group, visit: https://www.avisonyoung.com/en_CA/life-sciences